Effect of non-opiate antagonists on stereospecific opiate receptor binding of tritiated naloxone.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D001285:Atropine / Q000494:pharmacology*; D001667:Binding, Competitive / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D003994:Bucladesine / Q000494:pharmacology; D005374:Filtration; D005459:Fluorides / Q000494:pharmacology; D007545:Isoproterenol / Q000494:pharmacology*; D007981:Levorphanol / Q000494:pharmacology; D008297:Male; D051379:Mice; D009270:Naloxone / Q000378:metabolism*; D010643:Phenoxybenzamine / Q000494:pharmacology*; D010868:Pimozide / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology*; D011955:Receptors, Drug / Q000187:drug effects*; D013329:Structure-Activity Relationship; D013806:Theophylline / Q000494:pharmacology; D014316:Tritium
D000319:Adrenergic beta-Antagonists; D011955:Receptors, Drug; D010643:Phenoxybenzamine; D014316:Tritium; D010868:Pimozide; D007981:Levorphanol; D009270:Naloxone; D003994:Bucladesine; D001285:Atropine; D011433:Propranolol; D013806:Theophylline; D007545:Isoproterenol; D005459:Fluorides